Tamoxifen-loaded novel liposomal formulations: Evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis

Journal of Drug Targeting

Volumn 20, Issue 6, 2012, Pages 544-550

  Bhatia, Amit ^a   Singh, Bhupinder ^b   Raza, Kaisar ^b   Shukla, Anshuman ^b   Amarji, Basant ^b   Katare, Om Prakash ^b  

^a LOVELY PROFESSIONAL UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Chemoprevention; Liposomes; Phospholipid; Skin cancer; Topical delivery

Indexed keywords

ACETONE; DIMETHYLBENZ[A]ANTHRACENE; DRUG CARRIER; LIPOSOME; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPID; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUTION; ENCAPSULATION; FEMALE; HISTOPATHOLOGIC SKIN REACTION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; SKIN PAPILLOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; COCARCINOGENESIS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; LIPOSOMES; MICE; SKIN NEOPLASMS; TAMOXIFEN; TETRADECANOYLPHORBOL ACETATE; TREATMENT OUTCOME;

EID: 84861838104     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.694887     Document Type: Article

References (46)

1. Alfrevic A, Pirmohamed M. (2008). Pharmacogenetics of adverse drug reactions: a pharmacovigilance perspective. J Appl Ter Res, 6, 3-8.
2. Bagheri-Yarmand R, Hamma-Kourbali Y, Bissieres P, Morère JF, Crépin M. (2001). Carboxymethyl benzylamide dextran and tamoxifen combination inhibits tumor growth and angiogenesis. Clin Cancer Res, 7, 1805-1811.
3. Benson HA. (2010). Elastic liposomes for topical and transdermal drug delivery. Methods Mol Biol, 605, 77-86.
4. Betz G, Imboden R, Imanidis G. (2001). Interaction of liposome formulations with human skin in vitro. Int J Pharm, 229, 117-129.
5. Bhatia A, Bhushan S, Singh B, Katare OP. (2009). Studies on tamoxifen encapsulated in lipid vesicles: efect on the growth of human breast cancer MCF-7 cells. J Liposome Res, 19, 169-172.
6. Bhatia A, Kumar R, Katare O P. (2004). Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci, 7, 252-259.
7. Bhatia A, Singh B, Bhushan S, Katare OP. (2010). Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. Drug Dev Ind Pharm, 36, 350-354.
8. Boone CW, Kellof GJ, Malone WE. (1990). Identifcation of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res, 50, 2-9.
9. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. (2003). Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res, 42, 1-36.
10. Brauch H, Jordan VC. (2009). Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer, 45, 2274-2283.
11. Cevc G, Gebauer D, Stieber J, Schätzlein A, Blume G. (1998). Ultrafexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta, 1368, 201-215.
12. Chan S. (2002). A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol, 29, 129-133.
13. Choi MJ, Maibach HI. (2005). Elastic vesicles as topical/transdermal drug delivery systems. Int J Cosmet Sci, 27, 211-221.
14. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. (2012). Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm, 422, 229-237.
15. D'Agostini F, Izzotti A, Balansky RM, Bennicelli C, De Flora S. (2005). Modulation of apoptosis by cancer chemopreventive agents. Mutat Res, 591, 173-186.
16. D'Angelo E, Prat J. (2010). Uterine sarcomas: a review. Gynecol Oncol, 116, 131-139.
17. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. (2002). Chemoprevention of human skin cancer. Crit Rev Oncol Hematol, 41, 269-285.
18. El Maghraby GM, Williams AC, Barry BW. (2004). Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm, 276, 143-161.
19. Ferguson SE, Soslow RA, Amsterdam A, Barakat RR. (2006). Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol, 101, 322-326.
20. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir MJ, Sola B. (2003). The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. Ann N Y Acad Sci, 1010, 321-325.
21. Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M. (2006). New frontiers in intravesical therapies and drug delivery. Eur Urol, 50, 1183-93; discussion 1193.
22. Holden PR, McGuire B, Stoler A, Balmain A, Pitts JD. (1997). Changes in gap junctional intercellular communication in mouse skin carcinogenesis. Carcinogenesis, 18, 15-21.
23. Igawa Y, Keating AF, Rajapaksa KS, Sipes IG, Hoyer PB. (2009). Evaluation of ovotoxicity induced by 7, 12-dimethylbenz[a]anthracene and its 3,4-diol metabolite utilizing a rat in vitro ovarian culture system. Toxicol Appl Pharmacol, 234, 361-369.
24. Ishikawa TO, Kumar IP, Machado HB, Wong KP, Kusewitt D, Huang SC, Fischer SM, Herschman HR. (2010). Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis. Mol Oncol, 4, 119-125.
25. Jordan VC, Brodie AM. (2007). Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72, 7-25.
26. Katare OP, Raza K, Singh B, Dogra S. (2010). Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol, 76, 612-621.
27. Layek B, Mukherjee B. (2010). Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physicochemical properties. Sci Pharm, 78, 507-515.
28. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ, Lee JE. (2009). Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine, 16, 573-580.
29. Kramer R, Brown P. (2004). Should tamoxifen be used in breast cancer prevention? Drug Saf, 27, 979-989.
30. Li J, Tripathi RC, Tripathi BJ. (2008). Drug-induced ocular disorders. Drug Saf, 31, 127-141.
31. Manconi M, Marongiu F, Ennas G, Scano A, Sinico C, Valenti D, et al. (2008). Liposomes for (trans) dermal delivery of tretinoin: infuence of drug concentration and vesicle composition. J Drug Deliv Sci Techno, 18, 309-313.
32. Mura S, Manconi M, Valenti D, Sinico C, Vila AO, Fadda AM. (2010). Transcutol containing vesicles for topical delivery of minoxidil. J Drug Target, 19, 189-196.
33. O'Regan RM, Jordan VC. (2002). The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol, 3, 207-214.
34. Park BC, Paek SH, Lee YS, Kim SJ, Lee ES, Choi HG, Yong CS, Kim JA. (2007). Inhibitory efects of asiatic acid on 7,12-dimethylbenz[a] anthracene and 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. Biol Pharm Bull, 30, 176-179.
35. Perez EA. (2007). Safety profles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol, 18, viii26-viii35.
36. Puntoni M, Decensi A. (2009). The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. Eur J Cancer, 45 Suppl 1, 346-354.
37. Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare OP. (2011). Design and evaluation of fexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target, 19, 293-302.
38. Samaha HS, Kellof GJ, Steele V, Rao CV, Reddy BS. (1997). Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcafeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res, 57, 1301-1305.
39. Sengupta S, Jordan VC. (2008). Selective estrogen modulators as an anticancer tool: mechanisms of efciency and resistance. Adv Exp Med Biol, 630, 206-219.
40. Sinico C, Fadda AM. (2009). Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv, 6, 813-825.
41. Sirisabya N, Li Y, Jaishuen A, Zheng HG, Gershenson DM, Kavanagh JJ. (2008). Tamoxifen is safe and efective in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer, 18, 648-651.
42. Smith JJ, Tully P, Padberg RM. (2005). Chemoprevention: a primary cancer prevention strategy. Semin Oncol Nurs, 21, 243-251.
43. Trotta M, Peira E, Carlotti ME, Gallarate M. (2004). Deformable liposomes for dermal administration of methotrexate. Int J Pharm, 270, 119-125.
44. Urbinati G, Audisio D, Marsaud V, Plassat V, Arpicco S, Sola B, Fattal E, Renoir JM. (2010). Terapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model. Pharm Res, 27, 327-339.
45. Valenzano Menada M, Costantini S, Moioli M, Bogliolo S, Papadia A, Ferrero S, Dugnani MC. (2008). Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. Breast, 17, 631-636.
46. Villaseñor IM, Simon MK, Villanueva AM. (2002). Comparative potencies of nutraceuticals in chemically induced skin tumor prevention. Nutr Cancer, 44, 66-70.